Effective January 1, 2017, new precertification
requirements will apply to our commercial and Medicare Advantage HMO and PPO
members for the medical benefit drugs listed below:
- Cinqair® (reslizumab)
- Cubicin® (daptomycin)
- Darzalex™ (daratumumab)
- Erwinaze® (L-asparaginase)
- Exondys 51™ (eteplirsen)
- Faslodex® (fulvestrant)
- Hymovis® (high molecular weight viscoelastic
hyaluronan)
- Inflectra™ (infliximab)*
- Neulasta® (pegfilgrastim)*
- Neulasta® (pegfilgrastim) Onpro®*
- Sandostatin® LAR (octreotide acetate)
- Tecentriq™ (atezolizumab)
In addition, the following drugs are currently pending approval from the
U.S. Food and Drug Administration (FDA).
Once they receive FDA approval, they will also require precertification
approval from Independence:
- Cingal® (sodium hyaluronate/triamcinolone hexacetonide)
- Ocrevus™ (ocrelizumab)
- Remune® (HIV-1 immunogen)
These changes will be reflected in an updated precertification requirement
list, which will be posted to our website in December, prior to these changes going into effect. Look for
more information about the availability of this new precertification
requirement list in the December 2016 edition of Partners in Health
UpdateSM.
*Precertification requirements apply to all biosimilars
of infliximab and pegfilgratism approved by the FDA.